In the NE transformation setting, the pathway inhibitor samotolisib was combined with osimertinib in an EGFR-mutant PDX model of NE transformation.38 Even if the combination slowed tumor growth more than either monotherapy alone in this model, the response observed was modest. Here, EGFR is linked to neoplasm.